Mar 1 |
Bullish Tourmaline Bio Insiders Loaded Up On US$643.3k Of Stock
|
Feb 27 |
Tourmaline Bio to Present at Upcoming Investor Conferences
|
Feb 1 |
Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
|
Jan 29 |
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
|
Jan 25 |
Tourmaline Bio to raise ~$150M through public offering of shares
|
Jan 25 |
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
|
Jan 24 |
Tourmaline Bio looks to raise cash through a public offering
|
Jan 24 |
Tourmaline Bio Announces Proposed Public Offering of Common Stock
|
Jan 18 |
Tourmaline Bio: Time For A Pause
|
Jan 8 |
Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)
|